BiotechTube

Daptomycin + Comparator

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bacteremia

Conditions

Bacteremia

Trial Timeline

Nov 29, 2012 → Jan 20, 2016

NCT ID
NCT01728376

About Daptomycin + Comparator

Daptomycin + Comparator is a approved stage product being developed by Merck for Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT01728376. Target conditions include Bacteremia.

What happened to similar drugs?

1 of 4 similar drugs in Bacteremia were approved

Approved (1) Terminated (3) Active (1)
✅Vancomycin + DaptomycinMerckApproved
❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3
❌Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01728376ApprovedCompleted

Competing Products

9 competing products in Bacteremia

See all competitors
ProductCompanyStageHype Score
Daptomycin for InjectionMerckPhase 2
35
Vancomycin + DaptomycinMerckApproved
35
Ceftolozane-Tazobactam + MeropenemMerckPhase 3
32
Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
32
Aurexis®Bristol Myers SquibbPhase 2
35
ceftobiprole medocarilBasilea PharmaceuticaPhase 2
21
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
AP-SA02Armata PharmaceuticalsPhase 1/2
22
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22